Abstract: Herpes simplex virus 2 (HSV-2) is the leading cause of genital herpes and increases the risk of HIV infection, but there is no effective vaccine. A replication-defective HSV-2 mutant virus, dl5-29, is effective in animal models and has been in a phase I trial. Previous studies have shown that dl5-29 gives higher antibody responses and better protection when inoculated intramuscularly (IM) as compared with subcutaneously (SC). However, the basis for this effect has not been defined. We confirmed that IM inoculation of dl5-29 is more immunogenic and provides better protection than SC inoculation. IM inoculation of HSV-2 strains produced higher levels of a luciferase transgene than SC inoculation, as measured by intravital bioluminescence imaging. Intramuscular immunization also showed better protection against infection with a highly pathogenic African HSV-2, demonstrating that this single vaccine can be efficacious against HSV-2 strains from different geographic regions. 2. Abstract, line 26. Since the authors are measuring reporter gene expression instead of viral protein, I think they should change "virus-expressed proteins" to virus transgene expression" or "a reporter gene driven by a virus promoter."
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Introduction
Herpes simplex virus 2 (HSV-2) is the predominant cause of genital herpes infections worldwide and increases the risk of acquisition and transmission of HIV (Freeman et al., 2006; Roizman, Knipe, and Whitley, 2013; Wald et al., 2001) . It is an incurable sexually transmitted disease that can result in serious complications for newborns and immunocompromised patients. After initial infection of mucosal epithelial cells, HSV-2 spreads to sensory neurons in which it establishes a latent infection. Antiviral treatment can block viral replication and reduce symptoms during symptomatic disease. However, these drugs can neither prevent de novo infection or reactivation nor clear the latent virus. A few vaccines have been tested clinically in the last decade, some of which have shown to be safe, but none have succeeded in effectively preventing or treating HSV-2. New approaches are being tested to find safe and effective herpes vaccines. Some studies have used one or more HSV-2 glycoproteins as subunit vaccines to elicit neutralizing antibodies. Other approaches emphasize the inclusion of a few antigens proposed to induce cellular responses as well (Skoberne et al., 2013) . Alternatively, a replication-defective HSV-2 virus, dl5-29, was constructed that completes only part of the herpes lytic cycle. In normal cells, this virus produces 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 4 subcutaneous, intramuscular, or intradermal. Although some studies have shown that intranasal or intravaginal vaccination may elicit mucosal immunity and robust protection against HSV-2 (Jones, Taylor, and Knipe, 2000; Morrison, Da Costa, and Knipe, 1998; Shin and Iwasaki, 2012; Wu et al., 2009) , these approaches raise some safety concerns or could prove impractical to deliver. A number of groups have reported that their immunogens show better efficacy against HSV utilizing intramuscular delivery (Awasthi et al., 2012; Delagrave et al., 2012; Diaz and Knipe, 2016; Wang et al., 2012) . In particular, Delagrave et al. showed that intramuscular delivery of dl5-29 elicited higher antibody titers and better general protection from genital herpetic disease than subcutaneous or intradermal delivery (Delagrave et al., 2012) . In this study, we compare side-by-side the effects of subcutaneous and intramuscular routes of immunization on the efficacy of dl5-29 and examine the mechanisms of the enhanced efficacy of the IM route .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 5 Results HSV-2 dl5-29 virus protects better against genital herpes when administered intramuscularly. Previous studies have reported that IM immunization gives better protection against genital disease than other routes of inoculation (Delagrave et al., 2012; Diaz and Knipe, 2016; Awasthi et al., 2012) . We wished to confirm this and to determine the mechanism of this effect; thus, we first compared IM versus SC immunization with HSV-2 dl5-29 in our mouse infection system (Morrison, Da Costa, and Knipe, 1998) . Mice were primed and boosted with HSV-2 dl5-29 virus by the SC or IM routes and then challenged at day 54 with 50 LD 50 of the wild type (WT) HSV-2 G strain virus (LD 50 = 6x10 3 PFU) (Dudek et al., 2011) . Mock-immunized animals showed increasing degrees of disease over time after challenge with 100% of the animals becoming paralyzed during the first week ( Figure 1A ). All vaccinated animals showed reduced genital disease compared to the control group, and we detected virtually no genital disease in animals that had received intramuscular immunization ( Figure 1A ).
Significant differences in protection from disease were observed for the two routes of immunization (p=0.0005, two-way ANOVA). An important aspect of herpetic infection is viral shedding because infectious viruses can be shed from patients with no visible signs of disease. Therefore, it would be desirable for an HSV-2 vaccine to not only protect from disease but also reduce viral shedding (Bonneau et al., 1993) . SC immunization reduced viral shedding when compared to mock-vaccinated animals;
however, animals in this group still shed a significant amount of virus during the first week ( Figure 1B lymphocytes that produced interferon-γ. Once again, intramuscular immunization elicited a significantly higher cellular response (t-test p = 0.0027) ( Figure 2B ).
Total anti-HSV-2 antibody levels are higher after IM than after SC immunization.
By 3 weeks after immunization of BALB/c mice with dl5-29 virus, humoral responses to HSV-2 are detectable (Da Costa et al., 2000) . When virus stocks prepared from infected cell supernatants were used as the immunogen, the subcutaneous route produced antibody levels barely above those of the mock-immunized animals ( Figure   3A ). In contrast, intramuscular injection yielded higher levels of total anti-HSV antibodies ( Figure 3A , t-test p=0.0289). At day 37, 9 days after booster injection, BALB/c mice showed a robust humoral response against HSV-2 after both subcutaneous and intramuscular vaccination; however, the latter elicited much higher levels of anti-HSV antibodies ( Figure 3B , t-test p<0.0001). C57Bl/6 mice were available for humoral response assessment only at 3 weeks post priming because they were sacrificed for spleen harvesting a week after boosting. Their genetic background differs from that of the BALB/c strain, and we measured higher levels of total anti-HSV antibody in the vaccinated groups compared to the mock-immunized mice at 21 d post infection. In these animals as well, intramuscular vaccination elicited higher humoral responses ( Figure 3C , t-test p=0.0204).
Virus-encoded proteins are expressed in vivo from replication-defective HSV-2 strains. To test if the levels of viral gene expression were different by the two routes of immunization, we constructed an HSV-2 replication-defective viral strain, HSV-2 blue staining was detected in the injected muscle, and histological analysis showed that -galactosidase activity was present in muscle fibers and inflammatory cells ( Figure 5 ).
This supported the idea that viral antigens were synthesized de novo at the site of intramuscular injection and therefore persisted after the time of vaccination. In the case of subcutaneous vaccination, we detected no -galactosidase activity at or near the site of injection (results not shown). This suggested that the viral vaccine when delivered by the SC route was cleared and potentially processed by the immune system before the infection could be efficiently established. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 dl5-29 could be improved by IM delivery; thus, we compared the two routes of immunization in the context of intravaginal challenge with the South African HSV-2 SD90-3P virus (Colgrove et al., 2014; Dudek et al., 2011) . We observed greatly diminished disease severity in the IM vaccinated group as compared to the SC immunized animals (Figure 7 , panels A and C, p=0.0009 two-way ANOVA IM vs SQ), with disease scores similar to those observed after challenge with a U.S. HSV-2 strain 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11
Discussion
In this study, we have confirmed previous reports that IM immunization with genital herpes vaccines gives better protection against genital infection by providing better survival, reduced viral shedding, and reduced disease and increased antibody responses (Awasthi et al., 2012; Delagrave et al., 2012; Diaz and Knipe, 2016 
Mechanisms of increased IM immunogenicity.
Higher levels of protection and increased immunogenicity could be due to 1) higher levels of antigen expression; 2) prolonged expression of antigens; and/or 3) different antigen-presenting cells or different cytokine induction. In this study, we tested the first and second hypotheses, and we found that expression of proteins from an HSV-2 replication-defective recombinant virus was higher following intramuscular inoculation but not necessarily for longer periods of time. More sensitive and more frequent measurements of the kinetics of protein expression may show differences in the persistence of virus-encoded proteins, but our results using luciferase imaging show that this enzymatic level was at the level of detection by 3 d post infection.
Nevertheless, immunological epitopes may persist as fragments of the protein. In total, (Baar, 2010) , meaning that the tissue can respond rapidly to physiological changes by altering gene expression. This is thought to be accomplished by epigenetic regulation of muscle cell genes (Baar, 2010 
Implications for vaccine design.
We had previously observed that African HSV-2 isolates were more difficult to protect against than U.S. isolates using the SC route for immunization (Dudek et al., 2011) . This raised the possibility that there were different clades or strains of HSV-2 in various geographical areas that might require different vaccines or different genetic backbones for the vaccine virus. Because we had shown that IM immunization gave better protection than SC immunization against a U.S. challenge virus, we hypothesized that IM immunization might provide better protection against the African HSV-2 strains as well. Indeed, we observed that IM immunization with dl5-29 gave better protection against HSV-2 SD90 challenge infection than the historical data using SC immunization.
This protection was equivalent to that seen using U.S. challenge viruses, arguing that a different vaccine strain is not required for use against African strains. Accumulating data on HSV-2 sequence diversity are consistent with this. Genome sequences of 34 HSV-2 strains from around the world have shown less than 0.4% nucleotide divergence across the genome (Kolb et al., 2015 : Newman et al., 2015 ; therefore, HSV-2 is very 
Methods

Cells and Viruses.
Vero cells (ATCC CCL-81) were used for propagation and titration of WT virus stocks by plaque assay (Spang, Godowski, and Knipe, 1983) . The V529 (Ejercito, Kieff, and Roizman, 1968) , was obtained from Bernard Roizman and passaged <4 times in our laboratory. The HSV-2 SD90-3P virus derived from the SD90 virus, which was isolated from genital ulcer swab samples from an STD clinic in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 15 Carletonville, South Africa (Lai et al., 2003) . Viral cultures of SD90 were originally grown at the CDC, and extracellular samples were transferred to Harvard Medical School. The viruses were passed 3 times on Vero cells in our lab to prepare stocks.
The SD90-3P is a clonally derived virus derived from SD90 through three plaque purifications (Colgrove et al., 2014; Dudek et al., 2011) . For immunizations, virus was purified from cell culture supernatant. Briefly, infected cells were cultured at 34°C until CPE was observed. Heparin was added to a final concentration of 50 g/ml, and cells were transferred to 37°C for 6 h. Supernatant was collected and clarified by spinning at low speed (500 g for 10 min). Pellets were discarded, and medium containing virus was centrifuged at 20,000g for 90 min at 4°C. Pellets were resuspended in 5% glycerol in
PBS.
For vaginal challenges, virus was used as infected cell lysate. Infected cells were incubated at 34°C until full CPE was observed. Cells were detached from flask by shaking or using a cell scraper and pelleted by low speed centrifugation. Supernatant was discarded and pellets resuspended in a 1:1 mix of medium and sterile non-fat milk.
Cells were frozen/thawed once and sonicated for a total of 90 sec. Preparation was further clarified by low speed centrifugation.
Animal Studies.
Animal housing and experiments were conducted according to protocols approved by the Harvard Medical Area Standing Committee on Animals. of Depo-Provera in a 100l volume. At 4 weeks after the second immunization (day 56), the vaginal cavities were pre-swabbed with a wet polyester swab, and mice were then challenged by intravaginal infection with a dose of wild-type HSV-2 G or SD90-3P strains equivalent to 50 times the LD 50 (3.0x10 5 or 1.5x10 5 PFU respectively, as cell lysate preparation) in a 10 l volume using a micropipettor as described previously (Morrison, Da Costa, and Knipe, 1998) .
Assay of Acute Infection. On days 1-7 postinfection, the vaginal cavities of the mice were swabbed twice with pre-wetted polyester swabs. Each swab was placed in 1 ml of assay medium (DMEM, 0.1% glucose, 1% FCS, 5% glycerol) and stored at −80ºC. Viral titers were determined by standard plaque assay on Vero cells.
Clinical Observations. Wild-type HSV-2 infected mice were observed daily on days 1-14 for signs of genital lesions and systemic illness. The severity of disease was scored as previously defined: 0 = no sign of disease; 1 = slight genital erythema and edema ; 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 HSV gB SSIEFARL peptide (10 ng/ml) in a 37ºC, 5% CO 2 humidified incubator for 2 h, at which point Brefeldin A was added, and cells were incubated further for 4 h. Cells   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   19 were anesthetized with isoflurane, and D-luciferin (150 mg/Kg, in 150 l, Promega Cat.
#P1043) was injected SC in the scruff of the neck. Animals were imaged in an in vivo imaging system (IVIS) Lumina LT (Perkin Elmer) connected to a gas anesthesia system for 20-30 minutes to capture luminescence signal at its peak. Bioluminescence was quantified with Living Image imaging software (Perkin Elmer) and expressed as normalized radiance (photons/second/cm 2 /steradian).
Histochemistry and X-gal staining. Female CD-1 mice (Charles River) were immunized with 1x10 5 PFU of extracellular HSV-2 5BLacZ or a mix of 5BLacZ + dl5 as before. At 16 h post vaccination, mice were sacrificed by CO 2 asphyxiation, and the rear legs (including the skin in the rear flank for the SC route) were detached from the carcass and fixed (including the bone) in EM grade paraformaldehyde (EMS Cat# RT15700) on ice for 2 h. After rinsing in PBS, the gastrocnemius muscle was dissected from the leg and sliced with a surgical blade into pieces no more than 1-2 mm thick.
Tissue was stained with HistoMark X-gal (KPL Cat# 54-13-00) for 3 h at 37°C. The stained muscle was then extensively rinsed in PBS and placed in 70% ethanol. Noninfected tissue was processed in the same way as the HSV-2 5BLacZ infected muscle.
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